Despite the advance of newer immunotherapies and targeted agents for the treatment of RCC, high-dose IL-2 has an important role in achieving a durable response. Read my thoughts on when to consider it and which patients may benefit the most.
Explore this expert discussion of cytokine therapy in RCC, including current best practices, combinations with immunotherapy, and future directions; then download the slideset containing all the key data.
Dr. Brendan Curti explores the use of cytokine therapy in the treatment of RCC, including current best practices, combinations with immunotherapy, and future directions.
Download this PDF for guidance on the safe and effective use of HD IL-2 for patients with renal cell carcinoma.